down arrow

Quest Diagnostics, Inc.

  • Market Cap: Mid Cap
  • Industry: Miscellaneous
  • ISIN: US74834L1008
USD
184.18
1.57 (0.86%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

182.25185.12

52 Week

148.70197.55
Valuation
Technical
Day's Volume

CASH

1.04 M

Shareholding (Mar 2025)

FII

21.73%

Held by 344 FIIs

DII

35.69%

Held by 56 DIIs

Promoter

0.12%

How big is Quest Diagnostics, Inc.?

22-Jun-2025

As of Jun 18, Quest Diagnostics, Inc. has a market capitalization of $29.1 billion, with recent net sales of $10.2 billion and a net profit of $943 million.

Market Cap: As of Jun 18, Quest Diagnostics, Inc. has a market capitalization of 29,103.62 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Quest Diagnostics, Inc. reported net sales of 10,158.00 million and a net profit of 943.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 6,778.00 million, while total assets were reported at 16,153.00 million.

Read More

What does Quest Diagnostics, Inc. do?

22-Jun-2025

Quest Diagnostics, Inc. is a mid-cap provider of diagnostic information services, with recent net sales of $2.65 billion and a net profit of $234 million. Key financial metrics include a P/E ratio of 28.00 and a dividend yield of 117.62%.

Overview:<BR>Quest Diagnostics, Inc. is a provider of diagnostic information services operating in the Miscellaneous industry and is categorized as a mid-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,652 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 234 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 29,103.62 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Dividend Yield: 117.62% <BR>Debt Equity: 0.84 <BR>Return on Equity: 14.38% <BR>Price to Book: 4.20 <BR><BR>Contact Details:<BR>Address: 500 Plaza Dr, SECAUCUS NJ: 07094-3619 <BR>Tel: 1 973 5202700 <BR>Website: https://www.questdiagnostics.com/

Read More

Who are in the management team of Quest Diagnostics, Inc.?

22-Jun-2025

As of March 2022, the management team of Quest Diagnostics, Inc. includes Stephen Rusckowski (Chairman, President, and CEO), Dr. Daniel Stanzione (Lead Independent Director), and several Independent Directors: Vicky Gregg, Wright Lassiter, Timothy Main, and Denise Morrison. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Quest Diagnostics, Inc. includes the following individuals:<BR><BR>- Mr. Stephen Rusckowski, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Dr. Daniel Stanzione, who is the Lead Independent Director.<BR>- Ms. Vicky Gregg, an Independent Director.<BR>- Mr. Wright Lassiter, an Independent Director.<BR>- Mr. Timothy Main, an Independent Director.<BR>- Ms. Denise Morrison, an Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Quest Diagnostics, Inc. overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, Quest Diagnostics is fairly valued with a P/E ratio of 28, an EV to EBITDA of 17.29, and a Price to Book Value of 4.09, while achieving a year-to-date return of 21.52%, outperforming the S&P 500's 12.22%.

As of 30 June 2025, the valuation grade for Quest Diagnostics, Inc. has moved from attractive to fair. This suggests that the company is fairly valued at present. Key valuation ratios include a P/E ratio of 28, an EV to EBITDA of 17.29, and a Price to Book Value of 4.09. In comparison, peers such as IQVIA Holdings, Inc. have a higher P/E of 36.39, while Laboratory Corp. of America Holdings has a P/E of 29.20, indicating that Quest Diagnostics is positioned competitively within its industry.<BR><BR>In terms of recent performance, Quest Diagnostics has achieved a year-to-date return of 21.52%, significantly outperforming the S&P 500's 12.22% during the same period, although it lags behind the S&P 500 over longer horizons like 3 years and 5 years. Overall, the current valuation metrics suggest that Quest Diagnostics is fairly valued in the market.

Read More

Is Quest Diagnostics, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Quest Diagnostics has a mildly bullish technical trend, supported by bullish MACD and moving averages, while outperforming the S&P 500 year-to-date and over the past year, despite mixed signals in longer-term performance.

As of 3 October 2025, the technical trend for Quest Diagnostics, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance in both time frames. The daily moving averages also indicate a mildly bullish trend. However, the RSI shows no signal on both weekly and monthly charts, and Dow Theory indicates no trend in either time frame. <BR><BR>In terms of performance, Quest Diagnostics has outperformed the S&P 500 year-to-date and over the past year, with returns of 18.28% and 18.33% respectively, compared to the S&P 500's 14.18% and 17.82%. However, it has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is mildly bullish, supported by several bullish indicators, despite some mixed signals.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 17.67%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 10.91

 
3

Poor long term growth as Operating profit has grown by an annual rate 6.70% of over the last 5 years

 
4

Positive results in Jun 25

5

With ROCE of 11.44%, it has a expensive valuation with a 2.68 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 29,720 Million (Mid Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

87.16%

stock-summary
Debt Equity

0.76

stock-summary
Return on Equity

14.78%

stock-summary
Price to Book

4.11

Revenue and Profits:
Net Sales:
2,761 Million
(Quarterly Results - Jun 2025)
Net Profit:
295 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.26%
0%
2.26%
6 Months
5.97%
0%
5.97%
1 Year
14.94%
0%
14.94%
2 Years
33.96%
0%
33.96%
3 Years
22.41%
0%
22.41%
4 Years
17.27%
0%
17.27%
5 Years
49.39%
0%
49.39%

Quest Diagnostics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Quest Diagnostics Experiences Revision in Stock Evaluation Amidst Market Dynamics

Quest Diagnostics Experiences Revision in Stock Evaluation Amidst Market Dynamics

Quest Diagnostics, Inc. has recently seen a slight decline in stock price, currently at $178.43. Over the past year, the company achieved an 18.33% return, outperforming the S&P 500. Technical indicators show mixed signals, with bullish trends on monthly evaluations and a sideways movement expected in the short term.

Read More

Is Quest Diagnostics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Quest Diagnostics, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance in both time frames. The daily moving averages also indicate a mildly bullish trend. However, the RSI shows no signal on both weekly and monthly charts, and Dow Theory indicates no trend in either time frame. In terms of performance, Quest Diagnostics has outperformed the S&P 500 year-to-date and over the past year, with returns of 18.28% and 18.33% respectively, compared to the S&P 500's 14.18% and 17.82%. However, it has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is mildly bullish, supported by several bullish indicators, despite some mixed signals....

Read More

Is Quest Diagnostics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Quest Diagnostics, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance in both time frames. The daily moving averages are also mildly bullish. However, the RSI does not provide a signal, and Dow Theory indicates no trend on both weekly and monthly levels. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -5.11% and -0.10% compared to 1.09% and 4.15% for the index, respectively. However, it has outperformed the S&P 500 year-to-date and over the past year. Overall, the current technical stance is mildly bullish, supported by several bullish indicators, but tempered by recent underperformance in shorter time frames....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.92%
EBIT Growth (5y)
6.70%
EBIT to Interest (avg)
10.91
Debt to EBITDA (avg)
1.95
Net Debt to Equity (avg)
0.84
Sales to Capital Employed (avg)
0.82
Tax Ratio
22.45%
Dividend Payout Ratio
39.15%
Pledged Shares
0
Institutional Holding
99.50%
ROCE (avg)
17.67%
ROE (avg)
20.41%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
4.09
EV to EBIT
23.41
EV to EBITDA
17.29
EV to Capital Employed
2.68
EV to Sales
3.37
PEG Ratio
9.40
Dividend Yield
120.73%
ROCE (Latest)
11.44%
ROE (Latest)
14.38%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 158 Schemes (42.44%)

Foreign Institutions

Held by 344 Foreign Institutions (21.73%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.11% vs 1.18% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 26.07% vs 0.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,761.00",
          "val2": "2,652.00",
          "chgp": "4.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "568.00",
          "val2": "507.00",
          "chgp": "12.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "69.00",
          "val2": "72.00",
          "chgp": "-4.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-35.00",
          "val2": "-21.00",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "295.00",
          "val2": "234.00",
          "chgp": "26.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.90%",
          "val2": "138.40%",
          "chgp": "1.55%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.70% vs -6.38% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.33% vs -10.58% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9,872.00",
          "val2": "9,252.00",
          "chgp": "6.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,908.00",
          "val2": "1,790.00",
          "chgp": "6.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "226.00",
          "val2": "163.00",
          "chgp": "38.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-68.00",
          "val2": "-87.00",
          "chgp": "21.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "916.00",
          "val2": "904.00",
          "chgp": "1.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "143.30%",
          "val2": "146.00%",
          "chgp": "-0.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
2,761.00
2,652.00
4.11%
Operating Profit (PBDIT) excl Other Income
568.00
507.00
12.03%
Interest
69.00
72.00
-4.17%
Exceptional Items
-35.00
-21.00
-66.67%
Consolidate Net Profit
295.00
234.00
26.07%
Operating Profit Margin (Excl OI)
153.90%
138.40%
1.55%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.11% vs 1.18% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 26.07% vs 0.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
9,872.00
9,252.00
6.70%
Operating Profit (PBDIT) excl Other Income
1,908.00
1,790.00
6.59%
Interest
226.00
163.00
38.65%
Exceptional Items
-68.00
-87.00
21.84%
Consolidate Net Profit
916.00
904.00
1.33%
Operating Profit Margin (Excl OI)
143.30%
146.00%
-0.27%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 6.70% vs -6.38% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1.33% vs -10.58% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Quest Diagnostics, Inc. stock-summary
stock-summary
Quest Diagnostics, Inc.
Miscellaneous
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.
Company Coordinates stock-summary
Company Details
500 Plaza Dr , SECAUCUS NJ : 07094-3619
stock-summary
Tel: 1 973 5202700
stock-summary
https://www.questdiagnostics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."